Space Peptides（Taizhou）

Taizhou Xingputai Biopharmaceutical Co., LTD., based on the key research and development direction of peptide drugs planned by "Made in China 2025" and the strategic deployment of the "13th Five-Year Plan" biological industry Development Plan, is committed to providing integrated research and development and production services for global customers of innovative peptide drugs, and developing innovative peptide drugs with independent intellectual property rights. The company has built a large-scale medicinal polypeptide API project with an annual output of 3000kg in Taixing Economic Development Zone, covering an area of 120 mu. By integrating the world's top new drug discovery technology and leading intelligent manufacturing process, the company realizes the achievement transformation of new efficient green polypeptide synthesis process and intelligent high-end equipment. To build a CDMO intelligent factory with green and low-carbon production technology and high value-added polypeptide API products. Relying on the company's core competitiveness of innovative drugs, Xingputai will extend the large-scale production of innovative peptide drugs, and provide large-scale production of generic drugs covering the fields of anti-drug-resistant bacteria, antiviral, anti-rheumatoid, anti-coagulation, diabetes treatment, assisted reproduction and other peptide treatments. In addition, the company's new efficient synthesis process of peptides and the development of industrial automation equipment, using the international leading solid-liquid phase combination technology, combined with artificial intelligence database for accurate optimization of process parameters, to achieve the maximum atomic availability of each step of the peptide synthesis reaction, so as to significantly increase the yield and reduce the cost. The 40-80 steps of chemical reaction can be completed in a short time without interruption, to obtain high quality, high purity peptide API products.